Medical Care Technologies Inc. Introduces AI Breakthrough for Squamous Cell Carcinoma Detection

MESA, ARIZONA / ACCESS Newswire / September 22, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced a significant innovation in dermatological AI: a platform capable of detecting squamous cell carcinoma (SCC), the second most common skin cancer and a condition responsible for more than 15,000 deaths annually in the United States alone.

Early SCC detection is critical, as the cancer can spread to lymph nodes and distant organs if untreated. MDCE’s AI platform uses advanced machine learning classifiers to spot early warning signs invisible to patients during self-exams.

How the AI Detects SCC

The system applies edge-detection algorithms and keratin pattern recognition to flag:

By mapping lesions across the entire body and tracking their evolution, the system ensures that high-risk lesions are prioritized for clinical evaluation.

“Our AI doesn’t just take snapshots; it builds a timeline of skin health that uncovers hidden dangers before they escalate,” said Marshall Perkins, CEO of MDCE. “This technology has the potential to redefine how SCC is caught and treated worldwide.”

About Medical Care Technologies Inc.

Medical Care Technologies Inc. (OTC: MDCE) is building a portfolio of AI-powered health solutions spanning dermatology, neurology, and ocular care.

Company Websites: www.medicalcaretechnologies.com | www.mdcestock.com


Forward-Looking Statements: This press release contains forward-looking statements within the meaning of federal securities laws. Actual results may differ materially.

Contact:

Investor Relations
Medical Care Technologies Inc.
info@infiniteauctions.com
Website: www.mdcestock.com

SOURCE: Medical Care Technologies Inc. (OTC PINK:MDCE)

View the original press release on ACCESS Newswire

Staff

Recent Posts

BioSonic Bloom: What Published Research Says About 528 Hz and 432 Hz Audio Frequency Programs

An In-Depth Analysis of Digital Sound Frequency Programs, Binaural Beats Research, and Key Considerations for…

9 hours ago

Best TRT Injection for 2026: Fridays Lists Prescription Testosterone in Injectable and Oral Formats as Men Compare Telehealth Hormone Options

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research…

9 hours ago

How Does Ozempic Work For Weight Loss? Best Weight Loss Supplement Launch By PhenQ

Ozempic for Weight Loss: Does It Work and Is It Safe? Read PhenQ Details –…

9 hours ago

Best NAD+ Injection for 2026: Sprout Health Lists Compounded NAD+ at $149 First Month as Telehealth Longevity Programs Expand

Prescription NAD+ Injection Access, At-Home Administration Models, Compounding Standards, and What Consumers Should Know Before…

9 hours ago

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

1 day ago